Wegovy cuts liver fat to 3.1% in obese adults without diabetes
AI Summary- Novo Nordisk presented a post hoc analysis linking Wegovy to lower liver fat in obese adults without diabetes.
- 88.5% of 26 participants with baseline liver fat above 5% fell below that threshold by week 72.
- Novo Nordisk is investigating semaglutide 2.4 mg for MASH treatment in several markets.